Update on the Management of Aspirin-Exacerbated Respiratory Disease

다국어 초록 (Multilingual Abstract)

Aspirin-exacerbated respiratory disease (AERD) is an adult-onset upper and lower airway disease consisting of eosinophilic nasal polyps, asthma, and respiratory reactions to cyclooxygenase 1 (COX-1) inhibitors. Management includes guideline-based treatment of asthma and sinus disease, avoidance of COX-1 inhibitors, and for some patients aspirin desensitization followed by high-dose aspirin therapy. Despite this, many patients have inadequately controlled symptoms and require multiple sinus surgeries. In this review, we discuss the current standard approaches to the management of AERD, and we introduce several therapeutics under development that may hold promise for the treatment of AERD.

참고문헌 (Reference)

1 Christie PE, "Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects" 143 : 1025-1029, 1991

2 Sommer DD, "Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study" 152 : 42-47, 2015

3 Wenzel S, "The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study" 44 : 305-310, 2007

4 Berges-Gimeno MP, "The natural history and clinical characteristics of aspirin-exacerbated respiratory disease" 89 : 474-478, 2002

5 Ta V, "Survey-defined patient experiences with aspirin-exacerbated respiratory disease" 3 : 711-718, 2015

6 Park HS, "Sodium salicylate sensitivity in an asthmatic patient with aspirin sensitivity" 6 : 113-117, 1991

7 Marek L. Kowalski, "Seven Steps to the Diagnosis of NSAIDs Hypersensitivity: How to Apply a New Classification in Real Practice?" 대한천식알레르기학회 7 (7): 312-320, 2015

8 Chudwin DS, "Sensitivity to non-acetylated salicylates in a patient with asthma, nasal polyps, and rheumatoid arthritis" 57 : 133-134, 1986

9 Lee JY, "Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease" 119 : 157-164, 2007

10 Liu T, "Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes" 110 : 16987-16992, 2013

11 Cahill KN, "Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease" 135 : 245-252, 2015

12 Rajan JP, "Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients:a meta-analysis of the literature" 135 : 676-681.e1., 2015

13 Cowburn AS, "Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma" 101 : 834-846, 1998

14 Bel EH, "Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma" 371 : 1189-1197, 2014

15 Bobolea I, "Omalizumab:a potential new therapeutic approach for aspirin-exacerbated respiratory disease" 20 : 448-449, 2010

16 Gevaert P, "Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma" 131 : 110-116.e1., 2013

17 Bergmann KC, "Omalizumab in the treatment of aspirin-exacerbated respiratory disease" 3 : 459-460, 2015

18 Szczeklik A, "Natural history of aspirininduced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma" 16 : 432-436, 2000

19 Lee DK, "Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma" 24 : 226-230, 2004

20 Gevaert P, "Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis" 128 : 989-995.e1-8, 2011

21 Ortega HG, "Mepolizumab treatment in patients with severe eosinophilic asthma" 371 : 1198-1207, 2014

22 Pavord ID, "Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial" 380 : 651-659, 2012

23 Nair P, "Mepolizumab for prednisone-dependent asthma with sputum eosinophilia" 360 : 985-993, 2009

24 Haldar P, "Mepolizumab and exacerbations of refractory eosinophilic asthma" 360 : 973-984, 2009

25 McMains KC, "Medical and surgical considerations in patients with Samter’s triad" 20 : 573-576, 2006

26 Rozsasi A, "Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily" 63 : 1228-1234, 2008

27 Berges-Gimeno MP, "Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease" 111 : 180-186, 2003

28 Paruchuri S, "Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor" 206 : 2543-2555, 2009

29 Sestini P, "Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma" 153 : 572-575, 1996

30 Dahlén SE, "Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial" 165 : 9-14, 2002

31 National Asthma Education and Prevention Program, "Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007" 120 : S94-S138, 2007

32 Payne SC, "Evidence for distinct histologic profile of nasal polyps with and without eosinophilia" 121 : 2262-2267, 2011

33 Johns CB, "Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease" 28 : 287-289, 2014

34 Sladek K, "Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge" 149 : 940-946, 1994

35 Kieff DA, "Efficacy of montelukast in the treatment of nasal polyposis" 114 : 941-945, 2005

36 Berges-Gimeno MP, "Early effects of aspirin desensitization treatment in asthmatic patients with aspirinexacerbated respiratory disease" 90 : 338-341, 2003

37 Beck LA, "Dupilumab treatment in adults with moderate-to-severe atopic dermatitis" 371 : 130-139, 2014

38 Wenzel S, "Dupilumab in persistent asthma with elevated eosinophil levels" 368 : 2455-2466, 2013

39 Peters AT, "Diagnosis and management of rhinosinusitis: a practice parameter update" 113 : 347-385, 2014

40 Laidlaw TM, "Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes" 119 : 3790-3798, 2012

41 Yoshihide Kanaoka, "Cysteinyl Leukotrienes and Their Receptors; Emerging Concepts" 대한천식알레르기학회 6 (6): 288-295, 2014

42 Cummings HE, "Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor" 191 : 5807-5810, 2013

43 김윤정, "Cross-reactivity to Acetaminophen and Celecoxib According to the Type of Nonsteroidal Anti-inflammatory Drug Hypersensitivity" 대한천식알레르기학회 6 (6): 156-162, 2014

44 Yoshimura T, "Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma" 57 : 429-436, 2008

45 Healy E, "Control of salicylate intolerance with fish oils" 159 : 1368-1369, 2008

46 Klinkhardt U, "Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease" 73 : 232-241, 2003

47 Watkins PB, "Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma" 30 : 805-815, 2007

48 Woessner KM, "Cardiovascular prophylaxis and aspirin “allergy”" 33 : 263-274, 2013

49 Kim SH, "Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma" 35 : 585-590, 2005

50 Stevenson DD, "Aspirin-sensitive rhinosinusitis asthma: a doubleblind crossover study of treatment with aspirin" 73 : 500-507, 1984

51 Gollapudi RR, "Aspirin sensitivity:implications for patients with coronary artery disease" 292 : 3017-3023, 2004

52 Cahill KN, "Aspirin exacerbated respiratory disease:the search for a biomarker" 113 : 500-501, 2014

53 Stevenson DD, "Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes" 98 : 751-758, 1996

54 Świerczyńska-Krępa M, "Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study" 134 : 883-890, 2014

55 Macy E, "Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper" 98 : 172-174, 2007

56 Shaker M, "An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease" 121 : 81-87, 2008

57 Flood-Page P, "A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma" 176 : 1062-1071, 2007

58 Bochenek G, "A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge" 111 : 743-749, 2003